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Summary
 
Despite the development of an efficient specific immune response during measles virus (MV)
infection, an immunosuppression occurs contributing to secondary infections. To study the
role of nucleocapsid protein (NP) in MV-induced immunosuppression, we produced recombi-
nant MV NP. Purified recombinant NP exhibited biochemical, antigenic, and tridimensional
structure similar to viral NP. By flow cytometry, we showed that viral or recombinant NP
bound to human and murine B lymphocytes, but not to T lymphocytes. This binding was spe-
cific, independent of MHC class II expression, and dependent of the B lymphocyte activation
state. The murine IIA1.6 B cell line, deficient in the Fc receptor for IgG (Fc
 
g
 
RII) expression,
did not bind NP efficiently. Transfected IIA1.6 cells expressing either murine Fc
 
g
 
RIIb1 or b2,
 
or human Fc
 
g
 
RIIa, b1
 
*
 
, or b2 isoforms efficiently bound NP. Furthermore, this binding was
inhibited up to 90% by monoclonal antibodies 2.4G2 or KB61 specific for murine and human
Fc
 
g
 
RII, respectively. Finally, the in vitro Ig synthesis of CD40- or Ig-activated human B lym-
phocytes in the presence of interleukin (IL)-2 and IL-10 was reduced by 50% in the presence
of recombinant NP. These data demonstrate that MV NP binds to human and murine Fc
 
g
 
RII
and inhibits in vitro antibody production, and therefore suggests a role for NP in MV-induced
immunosuppression.
 
M
 
easles virus (MV)
 
1
 
 is responsible for an acute child-
hood disease that is benign in industrialized coun-
tries, but is among the primary causes of infant death in de-
veloping countries. MV belongs to the 
 
Morbillivirus 
 
genus
of the 
 
Paramyxoviridae 
 
family and its genome is a nonseg-
mented negative strand RNA encoding six structural pro-
teins: nucleocapsid protein (NP; 60 kD), phosphoprotein
(70 kD), matrix protein (37 kD), fusion (F) protein (with
subunits F1, 40 kD, and F2, 20 kD), hemagglutinin (H)
protein (80 kD), and large protein (250 kD). The minimal
infectious unit is the ribonucleoprotein complex composed
of the RNA tightly associated with the NP, phosphopro-
tein, and large protein.
MV infection is initiated by interaction between a viral
protein, the glycoprotein H, and a cellular receptor, the
human CD46 molecule (1, 2). The release of ribonucleo-
protein complex into the cytosol leads to genome tran-
scription, viral protein synthesis, and MV replication. The
humoral immune response is detected at the onset of the
rash, and the most abundant and rapidly produced antibod-
ies are specific for NP (3, 4). The cellular component of the
immune response against MV involves MHC class I–restricted
CD8
 
1
 
 T cells and MHC class II–restricted CD4
 
1
 
 T cells.
MV-specific MHC class II–restricted CD4
 
1
 
 T cells clones
have been isolated from PBL of healthy donors with a his-
tory of MV infection. Interestingly, the CD4
 
1
 
 T cell clones
were specific for the H, F, matrix, and NP proteins (5–7)
and most of them displayed cytotoxic activity. The anti-NP
T cells constitute an important component of the cellular
response against MV as NP-specific CD4
 
1
 
 T lymphocytes
can protect rats against MV-induced encephalitic disease (8).
In spite of the fact that NP is synthesized as a cytosolic
protein, the dual humoral and cellular CD4
 
1
 
 responses
against NP indicate that NP is both accessible to the B cell
receptor (BCR) after its release in the extracellular com-
partment and to the peptide-loading compartment after its
uptake by the APC. In this context, NP could be internal-
ized by APC either by fluid-phase endocytosis or by recep-
 
1
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tor-mediated endocytosis. Targeting a soluble exogenous
antigen to antigen-specific B cells via their BCR (9) or to
macrophages and dendritic cells via their FcR after its op-
sonization with specific antibodies (10, 11) results in an en-
hancement of MHC class II–restricted antigen presentation
to CD4
 
1
 
 T cells. However, it remains unknown whether
receptor-mediated endocytosis via BCR, FcR, or an NP-
specific cellular receptor could play a role in the induction
of the MHC class II–restricted NP presentation to CD4
 
1
 
 T
helper cells and subsequently in the high anti-NP antibody
synthesis.
MV infection gives rise to a paradoxical situation: despite
the development of an efficient immune response establish-
ing long-term immunity and virus elimination, an immuno-
suppression occurs that contributes to secondary infections
and mortality. This immunosuppression was first described
by Von Pirquet (12) who observed a suppression of tuber-
culin skin test reactivity during the acute phase of MV in-
fection and for several weeks thereafter. During the acute
phase of measles, lymphocytes from infected individuals re-
spond poorly to mitogens like PHA or PWM (13). More-
over, the production of cytokines from both lymphocytes
and monocytes is dysregulated (14) and antibody produc-
tion to the antigens of 
 
Salmonella typhi
 
 vaccine is impaired
(15, 16). Finally, a suppression of IgG synthesis was re-
cently reported in MV-infected human SCID mice (17).
The respective role of viral proteins in this immunosup-
pression remains unclear.
After vaccination, both immune response and immune
suppression are observed. In the majority of cases, children
immunized with live MV vaccine develop antibodies against
NP (18). Recent data reported that mitogen-induced lym-
phoproliferation was decreased at 3 mo after vaccination
with live attenuated MV, and was more pronounced in
children with the highest antibody response and immune
activation (19). MV vaccination may alter the T cell reper-
toire. Vaccination of infants with live attenuated MV vac-
cine induce changes in the circulating TCR V
 
b
 
 repertoire
since the V
 
b
 
4 subset was decreased and the V
 
b
 
2 subset was
increased (20). Such an alteration in the T cell repertoire
could be due to the presence of a viral superantigen as re-
ported for the rabies virus nucleocapsid that binds to V
 
b
 
8
and HLA class II 
 
a
 
 chain (21). In the present study, we
show that measles virus NP binds to human and murine Fc
receptor for IgG (Fc
 
g
 
RII) and that NP inhibits the in vitro
antibody synthesis from activated human B lymphocytes.
 
Materials and Methods
 
Cells and Antibodies.
 
Human cells were cultured in RPMI
1640 (GIBCO BRL, Life Technologies SARL, Cergy Pontoise,
France) supplemented with 10% FCS (TechGen, International,
Les Ulis, France), 10 mM Hepes, 2 mM glutamine, and 50 
 
m
 
g/
ml gentamicin (GIBCO BRL). Human B cells were purified
from tonsils by two successive rounds of T cells depletion by ro-
setting with sheep red blood cells (Biomérieux, Lyon, France).
Tonsils were finely minced, the cell suspension (10
 
7
 
 cells/ml) was
mixed with 0.02 vol of packed sheep red blood cells, and 30 ml
were layered over 15 ml of Ficoll (Eurobio, Les Ulis, France).
Cells were centrifuged at 50 
 
g
 
 for 15 min and at 800 
 
g
 
 for 30 min.
B cells were recovered from the interface between medium and
Ficoll and were washed before another round of depletion. T
cells were purified from tonsils by two successive passages on ny-
lon wool columns. B and T cell preparations were routinely
 
.
 
98% and 
 
.
 
90% pure, respectively, as revealed by their pattern
of expression of CD20 and CD3 (Dako, Trappes, France). Rabbit
anti-human Igs coupled to polyacrylamide beads were purchased
from Bio-Rad S.A. (Ivry Sur Seine, France) and used at a final
dilution of 1:600 to stimulate B cells during 2 d. PHA (Sigma-
Aldrich Chimie SARL, Saint Quentin Fallavier, France) was used
at 5 
 
m
 
g/ml to stimulate T cells during 3 d.
The following human cell lines have been used in the course
of this study: HUT78 (T lymphoma), JY (lymphoblastoid cell line),
cell line clone 13 (Cl.13) mutant derived from JiJoye (22), Raji
(B Burkitt lymphoma), and the MHC class II–deficient cell lines
RM2, RM3, and RJ2.2.5 (23, 24) derived from Raji.
The IIA1.6 B cell line is a Fc
 
g
 
RII-negative variant of the
mouse A20/2J B lymphoma. IIA1.6 cells transfected with murine
Fc
 
g
 
RII cDNA B1 and B2 were a gift from C. Bonnerot and S.
Amigorena (Institut National de la Santé et de la Recherche Méd-
icale CJF9501, Institut Curie, Paris, France; reference 10) and
IIA1.6 cells expressing human Fc
 
g
 
RIIa, b1
 
*
 
, and b2 isoforms were
provided by J.G.J. Van de Winkel (University Hospital, Utrecht,
The Netherlands; reference 25). Fc
 
g
 
RIIb1
 
*
 
 is a variant of
Fc
 
g
 
RIIb1 that contains a single amino acid difference in the cy-
toplasmic tail.
The murine cell lines M12 (B lymphoma) and 408 (T hybrid-
oma), and the simian fibroblast cell line Vero were grown in DME
supplemented with 6% FCS, 10 mM Hepes, 2 mM glutamine,
50 
 
m
 
M 2-mercaptoethanol, and 50 
 
m
 
g/ml gentamicin (GIBCO
BRL). The anti-NP mAb 25
 
a
 
NP was purified from culture of
hybridoma anti-NP clone 25 (26). The rat mAb 2.4G2 recogniz-
ing murine Fc
 
g
 
RII (27) and mouse mAb KB61 recognizing hu-
man Fc
 
g
 
RII (CD32), provided by D.Y. Mason (John Radcliffe
Hospital, Oxford, U.K.; reference 28), were used for inhibition
experiments.
 
Production of Recombinant NP.
 
AcNPV (
 
Autographa californica
 
 nu-
clear polyedrosis virus) and recombinant virus stocks were grown
and assayed in confluent monolayers of Sf (
 
Sporodoptera frugiperda
 
)-9
cells in TGV 3 (TC 100 modified medium) containing 10% FCS.
Sf9 cells and AcNPV virus were obtained from G. Devauchelle
(Institut National de la Recherche Agronomique–Centre Na-
tional de Recherche Scientifique, St. Christol lez Alès, France).
The cDNA for the NP of measles virus (Hallé strain) was de-
scribed by R. Buckland et al. (29) and was inserted in the transfer
vector pGmAc 34 (G. Devauchelle) at the SmaI site. The recom-
binant transfer vector pGmacNP contained the cDNA of NP un-
der the control of the polyhedrin promoter. Sf9 cells were trans-
fected with a mixture of plasmid pGmacNP and wild-type AcNPV
DNA. Recombinant baculovirus AcNPVNP were plaque purified.
 
Purification of Recombinant and Viral NP.
 
Recombinant NP was
purified from confluent monolayers of Sf9 cells infected with vi-
rus AcNPVNP at a multiplicity of 1 PFU/cell. 2 
 
3
 
 10
 
8
 
 infected
cells were harvested 3 d after infection by centrifugation at 200 
 
g
 
and washed 3 times in PBS. Purified NP were prepared from
these cells using modifications of the previously described method
for preparation of intracellular measles virus nucleocapsids (30).
Cell pellets were resuspended in hypotonic buffer (10 mM Tris-
HCl, pH 7.5, 10 mM NaCl) at 2 
 
3
 
 10
 
7
 
 cells/ml in the presence
of proteinase inhibitors (0.1 mM 3,4-dichloroisocoumarin, 0.02
mM E-64, 0.1 mM 1,10-Phenantroline; Sigma-Aldrich Chimie 
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SARL). Cells were lysed by the addition of the nonionic deter-
gent Nonidet P-40 to a final concentration of 1% (vol/vol) and
left on ice for 30 min. Nuclei were removed by centrifugation at
1,000 
 
g
 
 at 4
 
8
 
C for 5 min, and the supernatant was adjusted to
contain 10 mM EDTA. This fraction was then clarified of partic-
ulate material by centrifugation at 10,000 
 
g
 
 at 4
 
8
 
C for 10 min.
This cytoplasmic extract was centrifuged through a discontinuous
density gradient in SW 41 centrifuge tubes (Beckman Instrs.,
France SA, Gagny, France). The step gradient was comprised of 2
ml of 40% (wt/vol) CsCl, 2 ml of 30% CsCl, 2 ml of 25% CsCl,
and 2 ml of 5% (wt/vol) saccharose each containing 25 mM Tris-
HCl, pH 7.5, 50 mM NaCl, 2 mM EDTA, and 0.2% (wt/vol)
sodium lauroyl sarcosinate. Centrifugation was performed at
12
 
8
 
C for 2 h at 36,000 rpm. The dense visible band observed in
the 30% CsCl step was removed by needle aspiration, diluted in
PBS, and centrifuged in a rotor (SW 41; Beckman Instrs. France
SA) at 12
 
8
 
C for 2 h at 36,000 rpm. The NP pellet was solubilized in
1 ml of PBS, aliquoted, and stored at 
 
2
 
80
 
8
 
C.
Viral NP was purified from Vero cell line infected with Hallé
strain of measles virus at 0.01 PFU/cell and cultured in DME 2%
FCS at 33
 
8
 
C. The cells were harvested 4 d later when 80% of the
cells formed syncytia. The cells were scraped and centrifuged at
200 
 
g
 
 for 10 min and washed three times in PBS. Cell pellets
were resuspended in hypotonic buffer, and cells were lysed as
with Sf9 infected cells. NP purification was performed as de-
scribed for recombinant NP purification.
 
Protein Analyses.
 
Cytoplasmic extract of Sf9-infected cells or
purified NP were subjected to 10% SDS-PAGE. Gels were stained
with Coomassie brilliant blue R-250 or electroblotted onto a ni-
trocellulose membrane using a semidry blotting system (Biometra,
Göttingen, Germany). The NP was identified with mAb 25
 
a
 
NP
and alkaline phosphatase-conjugated anti–mouse Ig (Bio-Rad S.A.).
The NBT/BCIP system (Bio-Rad S.A.) was used for colorimet-
ric detection. The protein concentration was determined using
the copper-dependent BCA assay (Pierce Chem. Co., Rockford,
IL) in microtiter plate with bovine serum albumin as a standard.
 
Flow Cytometry.
 
Cells (5 
 
3
 
 10
 
5
 
) were incubated for 1 h at
4
 
8
 
C with purified NP (5 
 
m
 
g) in 100 
 
m
 
l of PBS containing 1%
BSA and 0.1% NaN
 
3
 
. Cells were then washed three times in this
solution and incubated with mAb 25
 
a
 
NP or biotinylated 25
 
a
 
NP
for 30 min at 4
 
8
 
C. After three washes, cells were incubated with
FITC-conjugated donkey anti–mouse IgG (Jackson ImmunoRe-
search Labs., West Grove, PA) or with streptavidin conjugated to
FITC (Jackson Laboratory) for 30 min at 4
 
8
 
C, and then washed.
Flow cytometric analyses were performed on a FACScan
 
Ò
 
 (Becton
Dickinson, Immunocytometry Systems, Rungis, France). The
median fluorescence intensity value was chosen to quantify NP
binding. For antibody inhibition experiments, the value obtained
for control without NP was subtracted for each point and the
value obtained without antibody was considered as 100%.
 
NP Biotinylation and Competition.
 
NP was biotinylated with suc-
cinimidyl-6-(biotinamido)hexanoate (Pierce Chem. Co.) for 2 h
at 4
 
8
 
C and then dialyzed in PBS. Biotinylated NP binding on
Cl.13 cell line was detected with FITC-conjugated streptavidin
by FACS
 
Ò
 
 analysis. For competition experiments, 2 
 
m
 
g of biotin-
ylated NP were incubated with 0–85 
 
m
 
g of unlabeled NP. FITC-
conjugated streptavidin was used to detect the remaining biotin-
ylated NP binding and values of median fluorescence intensity
measured. The value obtained for the control without NP was
subtracted for each point to determine the percentage of NP bind-
ing. The number obtained for 2 
 
m
 
g of biotinylated NP was con-
sidered as 100%.
 
In Vitro Human Antibody Production.
 
Purified B cells were seeded
at 2 
 
3
 
 10
 
5
 
 cells/well in round-bottomed 96-well microtiter trays
in a final volume of 0.25 ml and were stimulated with rabbit anti–
human Igs coupled to polyacrylamide beads (1/600) or 2 
 
3
 
 10
 
4
 
mitomycin C–treated Ltk
 
2
 
 cells stably transfected with the CD40
ligand (CD40L; gift of M. Bakkins, Vrije Universiteit, Brussels,
Belgium). Purified recombinant IL-2 and IL-10, provided by A.
Minty (Sanofi, Labège, France) and J. Banchereau (Schering-
Plough, Dardilly, France), respectively, were used at 10 U/ml
and 50 ng/ml. Purified NP was added at the onset of the culture
at the optimal concentration of 30 ng/ml. Ig secretion (IgG, IgM,
and IgA) was determined in 12-d culture supernatants by standard
ELISA techniques, as described elsewhere (31). The percentage
of inhibition in the presence of NP was calculated on the basis of
maximal stimulation without NP.
 
Results
 
Recombinant and Viral NP Exhibit Similar Biochemical and
Antigenic Characteristics.
 
As the measles nucleocapsids are
difficult to purify and are often degraded in mammalian
cells (32), we used the recombinant baculovirus technology
to produce high level of measles NP in insect cells. We ob-
served that the recombinant NP reached the maximal level
of expression in Sf9 cells by 3 d after infection with recom-
binant AcNPVNP.
As estimated from SDS-PAGE analysis, NP represented
 
z
 
10% of total soluble proteins 3 d after infection (Fig. 1 
 
A
 
,
lanes 1 and 2). We took advantage of the nucleocapsid for-
mation in insect cells to purify them using centrifugation
on CsCl gradients as previously described for viral nucleo-
capsids isolation (30). The recombinant NP formed a dense
visible band in the 30% CsCl step gradient. This single-step
gradient purification was sufficient to obtain homogenously
purified NP that could be pelleted. Purified NP analyzed
by SDS-PAGE (Fig. 1 A, lane 3) migrated as two molecu-
lar species of about 60 kD; the larger one was predominant
and co-migrated with the viral NP (data not shown). Both
bands were recognized by mAb 25aNP (Fig. 1 B, lane 3)
that recognized no polypeptide in insect cells infected with
Figure 1. Measles NP purification from Sf9 cells infected with recom-
binant baculovirus AcNPVNP. Sf9 cells were infected with wild-type
AcNPV or recombinant AcNPVNP and the cells harvested 3 d after in-
fection. Proteins recovered from the cell extracts or NP purified on CsCl
gradient were separated by SDS-PAGE and stained with Coomassie bril-
liant blue (A) or analyzed by Western blot using mAb 25aNP (B). Mo-
lecular weight markers are shown on the left. Lane 1, Sf9 infected with
AcNPV; lane 2, Sf9 infected with AcNPVNP; lane 3, purified NP.272 FcgRII Is a Receptor for Measles Virus Nucleocapsid Protein
wild-type AcNPV (Fig. 1 B, lane 1). The minor band
probably represents a cleavage product of the major one as
it became more abundant in cells harvested later. Under
these conditions, the purification yield was z50% and re-
sulted in the isolation of 1 mg of pure recombinant NP
from 108 infected insect cells.
Electron microscopy analysis (data not shown) con-
firmed the assembly of recombinant NP in nucleocapsids
similar to measles nucleocapsids (33). These observations
show that the insect cell expression system permits the pro-
duction of large quantities of purified NP that preserve its
native structure.
NP Binds to Human and Murine B Cells. Tonsillar human
B and T lymphocytes were incubated with variable amounts
of recombinant or viral NP and assayed for NP binding by
flow cytometry. Only B lymphocytes bound both recom-
binant and viral NP (Fig. 2, A and C). T lymphocytes
failed to do so (Fig. 2, B and D).
In the course of this study, we observed that the propor-
tion of B cells susceptible to bind NP was variable and
ranged between 65 and 90%. Since different tonsil speci-
mens were used for each experiment, this observation sug-
gested that NP binding could be modulated after B cell ac-
tivation. The data shown in Fig. 3 indicate that the level of
NP binding to anti–Ig-activated B lymphocytes (Fig. 3 B;
median 107.5) was significantly higher than for unstimu-
lated B lymphocytes (Fig. 3 A; median 62.6). As summa-
rized in Table 1, a similar increase in NP binding was also
observed in the human B lymphoblastoid cell line JY after
anti-Ig stimulation. In contrast, PHA-activated T lympho-
cytes or HUT78 lymphoma cells did not bind NP (Table
1). Moreover, Burkitt lymphoma or lymphoblastoid cell
lines were both able to bind NP (Table 1).
Binding studies were performed with the Cl.13 cell line,
a mutant cell line derived from JiJoye, that bound NP very
efficiently (Table 1) and biotinylated recombinant NP. NP
binding was saturable and the maximal binding capacity
derived from these experiments was 8 mg/5 3 105 cells
(133 pmol/5 3 105 cells; Fig. 4 A). Competition experi-
ments indicated that a 25-fold excess of unlabeled NP was
required to inhibit, by 93%, biotinylated NP binding (Fig.
4 B). Altogether, these results indicate that the Cl.13 cell
line express a specific membrane receptor for NP.
To determine whether NP could be a superantigen, we
tested if the NP binding was dependent on MHC class II
molecule expression. As mentioned before, PHA-activated
T cells or HUT78 cells, which both express MHC class II
molecules, did not bind NP. Moreover, equivalent levels of
NP binding were obtained using RJ2.2.5, RM2, and RM3
MHC class II–deficient mutants of the Raji cell lines as
well as the wild-type MHC class II–expressing Raji (Table
1). These results clearly indicate that NP binding is inde-
pendent of MHC class II expression.
Murine B lymphocytes and various murine B cell lines
were then tested for their ability to bind NP. NP binding
was observed to murine splenic B cells and to the B lym-
phoma cell line M12 (Table 1). In contrast, no significant
NP binding was detected to splenic T cells or the T cell
hybridoma 408 (Table 1).
Taken together, these findings indicate that the binding
of NP to lymphocytes is: (a) specific and restricted to the B
cell lineage, (b) increased after B cell activation, and (c) in-
dependent of MHC class II expression. The only exception
was the murine IIA1.6 cell line derived from the B cell
lymphoma A20 (Table 1).
Figure 2. FACSÒ analysis of recombinant and viral NP binding to hu-
man B and T lymphocytes. Purified B cells (A and C) and purified T cells
(B and D) were isolated from tonsils and incubated for 1 h with 5 mg of
purified recombinant NP (A and B) or 5 mg of purified viral NP (C and
D). NP binding was revealed with mAb 25aNP and FITC-conjugated
donkey anti–mouse IgG (—— ). Cells were either incubated with mAb
25aNP and FITC-conjugated donkey anti–mouse IgG (...) or FITC-
conjugated donkey anti–mouse alone (——) as controls.
Figure 3. FACSÒ analysis of NP binding to anti-Ig activated B lym-
phocytes. Purified B lymphocytes were cultured for 2 d in the presence
(B) or in the absence (A) of anti–human Ig coupled to beads. Cells were
incubated with 2.5 mg of recombinant NP. NP binding was revealed with
biotinylated mAb 25aNP and FITC-conjugated streptavidin (—— ).
Cells were either incubated with biotinylated mAb 25aNP and FITC-
conjugated streptavidin (...) or FITC-conjugated streptavidin alone (——)
as controls.273 Ravanel et al.
FcgRII Is a B Cell–specific Receptor for NP. As IIA1.6 cells
are deficient for FcgRII expression, we investigated whether
FcgRII could be involved in NP binding. To test this hy-
pothesis, murine splenocytes were incubated with recom-
binant NP in the presence or absence of mAb 2.4G2 rec-
ognizing murine FcgRII. As shown in Fig. 5 B, the NP
binding was abolished by mAb 2.4G2. To further explore
the nature of the NP receptor expressed by B cells, two
variants of the IIA1.6 cell line expressing the murine
FcgRIIb1 or b2 isoforms were used. As illustrated in Fig. 5,
expression of FcgRIIb1 or b2 allowed IIA1.6 cells to effi-
ciently bind NP. Moreover, the addition of mAb 2.4G2
inhibited NP binding to both transfectants by 86 and 88%
for the FcgRIIb1 and b2, respectively. These results support
the notion that murine FcgRII are specific NP receptors.
We next tested the ability of NP to bind to human FcgRII
using IIA1.6 cell line expressing the human FcgRIIa, b1*,
or b2 isoforms. As shown in Fig. 6, all FcgRII transfectants
bind NP efficiently. Furthermore, the NP binding was in-
hibited by the CD32-specific mAb KB61 to IIA1.6 cells
expressing FcgRIIa, b1*, or b2 (92, 89, and 81% inhibition
of NP binding, respectively). Similar binding experiments
performed on tonsillar B lymphocytes showed that mAb
KB61 also inhibits the NP binding on normal B cells by up
to 76% (data not shown). Taken together, these observa-
tions demonstrate that both murine and human FcgRII are
receptors for measles virus NP.
NP Inhibits the In Vitro Ig Synthesis. It has long been known
that immune complexes can exert a negative feedback on B
cell responses via FcgRII (34). The three-dimensional struc-
ture of the NP could induce cross-linking of the FcgRII
expressed on B cells and mimics the antagonistic signal evoked
by immune complexes. To test this possibility, purified tonsil-
lar B cells were costimulated with IL-2, IL-10, and either im-
mobilized anti-Ig antibodies or a CD40L transfectant, in the
presence or absence of an optimal dose of recombinant NP.
The combination of IL-2 and IL-10 was chosen with regard
to its capacity to efficiently stimulate Ig synthesis (35). De-
termination of the polyclonal IgM, IgG, and IgA secretion
after a 12-d culture period was chosen as the read-out system.
As shown in Table 2, IL-2 and IL-10 elicited a strong
polyclonal antibody response both in the anti-Ig and in the
CD40L systems. Addition of NP in the cultures resulted in
a significant inhibition of the Ig response (ranging between
49 and 62%), irrespective of the isotype considered. This
finding suggests that the binding of NP to the FcgRII
downmodulates the capacity of B cells to differentiate into
Ig-secreting cells.
Discussion
In the present study, we have shown that viral or recom-
binant NP can bind to the surface of B cells. This NP bind-
ing is specific, restricted to the B cell lineage both in humans
and mice, increased after B cell activation, and does not re-
quire MHC class II expression. We also demonstrated that
the murine and human FcgRII are receptors for measles vi-
rus NP and that the binding of NP inhibits the Ig synthesis
by activated B cells.
Table 1. NP Binding on Human and Murine Lymphocytes
Cells MHC class II NP binding
Human lymphocytes
B 11 1
B 1 aIg 1 111
T 22
T 1 PHA 12
Human cell lines
JY (BEBV) 11
JY 1 aIg 11 1
C1.13 (Burkitt) 11 1
Raji (Burkitt) 11
RJ2.2.5 21
RM2 21
RM3 21
HUT78 12
Murine lymphocytes
B 11 1
T 22
Murine cell lines
M12 11
IIA1.6 12
hybridoma T 408 22
NP binding was detected as described in Fig. 2. The staining intensity
estimated by the median fluorescence intensity is indicated by the num-
ber of minus or plus signs (2, median ,6; 1, median between 6 and
20; 11, median between 20 and 80; 111, median between 80 and
300). BEBV, B lymphoblastoid cell line.
Figure 4. Specificity of NP
fixation on Cl.13 cell line. (A)
Dose-dependent binding of bi-
otinylated NP. The median in-
tensity value of the fluorescence
histograms are indicated. FITC-
conjugated streptavidin was used
for the detection of NP binding.
(B) Competition between unla-
beled NP and biotinylated NP.
The Cl.13 cell line was incubated
with 2 mg of biotinylated NP and
various amounts of unlabeled NP.
Percentages of biotinylated NP
binding detected as above was
calculated as indicated in Materi-
als and Methods.274 FcgRII Is a Receptor for Measles Virus Nucleocapsid Protein
To produce large quantities of recombinant NP, we de-
veloped a baculovirus expression system. The recombinant
NP exhibits similar biochemical and antigenic characteris-
tics of viral NP. In agreement with Fooks et al. (36), we
observed that in the absence of other viral proteins, NP
could self-assemble into nucleocapsid-like structures very
similar to those observed for measles nucleocapsids (data
not shown and reference 33). Such particles were also ob-
served in mammalian cells infected with recombinant vac-
cinia virus expressing NP (37). The recombinant NP thus
presents a native structure suitable for binding and func-
tional studies.
Binding studies using biotinylated NP showed a satura-
tion of NP binding to Cl.13 cell line and a competition
with unlabeled NP indicating that NP binding on B cells is
specific. Rabies N protein was previously described as a
human viral superantigen that binds to the HLA class II a
chain (21). However, our results show that MV NP bind-
ing is independent of MHC class II expression, suggesting
that it is unlikely to behave as a superantigen. Conse-
quently, NP is probably not directly involved in the alter-
ations of the T cell repertoire observed after MV vaccina-
tion (20).
Among the various human or mouse B cell lines tested,
only one, the IIA1.6 mutant, did not bind NP efficiently. The
fact that this mutant does not express FcgRII prompted us
to examine whether the low-affinity IgG receptor (FcgRII;
CD32) could be a cellular receptor for NP. Human B cells
Figure 5. NP binding to mouse FcgRII transfectants and inhibition of
NP binding by mAb 2.4G2. Spleen cells (A and B), cell lines IIA1.6 (C
and D), IIA1.6 expressing murine FcgRIIb1 (E and F), or FcgRIIb2 (G
and H) were incubated with 5 mg of NP in the absence (A, C, E, and G)
or in the presence (B, D, F, and H) of mAb 2.4G2. NP binding was de-
tected with biotinylated mAb 25aNP and FITC-conjugated streptavidin
(—— ). Cells were either incubated with biotinylated mAb 25aNP and
FITC-conjugated streptavidin (...) or FITC-conjugated streptavidin alone
(——) as controls.
Figure 6. NP binding to human FcgRII transfectants and inhibition of
NP binding by mAb KB61. Cell lines IIA1.6 (A and B), IIA1.6 expressing
human FcgRIIa (C and D), FcgRIIb1* (E and F), or FcgRIIb2 (G and
H) were incubated with 5 mg of NP in the absence (A, C, E, and G) or in
the presence (B, D, F, and H) of mAb KB61. NP binding was detected
with biotinylated mAb 25aNP and FITC-conjugated streptavidin (—— ).
Cells were either incubated with biotinylated mAb 25aNP and FITC-
conjugated streptavidin (...) or FITC-conjugated streptavidin alone (——)
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preferentially express FcgRIIb and phagocytic cells FcgRIIa
molecules. Two different FcgRIIb isoforms are generated
by alternative splicing, IIb1 and IIb2, which are identical
except for a 19– or a 47–amino acid insertion in the cyto-
plasmic tail of the mouse or human IIb1 isoform, respec-
tively. On mouse B cells, only the IIb1 form is expressed,
the IIb2 molecules being mainly expressed on myeloid
cells. Human and mouse IIb2 isoforms mediate endocytosis
of their ligands, whereas human IIa isoform is favoring
phagocytosis (10, 25). FcgRIIa bears a 26–amino acid im-
munoreceptor tyrosine-based activation motif in its intrac-
ytoplasmic domain involved in stimulatory functions (38).
The immunoreceptor tyrosine-based activation motif is re-
placed by a 13–amino acid immunoreceptor tyrosine-based
inhibitory motif in the intracytoplasmic domain of FcgRIIb
isoforms. This motif has been previously shown to be re-
quired for the inhibition of the antiimmunoglobulin-induced
B cell activation by immune complexes (10, 25). When
IIA1.6 cells transfected with expression vectors encoding
either for murine FcgRIIb1 or b2 isoforms or human
FcgRIIa, b1*, or b2 isoforms, all transfectants efficiently
bound recombinant NP. This binding was specific since it
was inhibited by mAb directed against human or murine
FcgRII. These results demonstrate that murine and human
FcgRII are specific NP receptors. However, since the inhi-
bition of NP binding with specific anti-FcgRII antibody
was never complete and a very low NP binding could be
detected to the IIA1.6 cells, we can not definitively ex-
clude the presence of another cell-surface receptor for NP.
The mAb 2.4G2 blocks the interaction between murine
FcgRII and immune complexes, but also inhibits the NP
binding to FcgRII, thus suggesting that immune com-
plexes and NP share the same binding site on FcgRII. The
central core (amino acids 189–373) of NP is essential for
NP–NP interaction (39) and is probably not accessible for
FcgRII interaction. By contrast, the NH2- or COOH-ter-
minal regions seem to be accessible to antibodies directed
against NP (40), and thus could be involved in the interac-
tion with FcgRII. Several genotypes have been described
for MV, but variations between strains of a same genotype
is small. Moreover, for group A, comprising all the vaccine
strains like Hallé, no more than one nucleotide difference
was found in the nucleotide sequence encoding NP (41).
During the acute phase of measles infection, high amounts
of NP-specific antibodies are produced suggesting an inter-
action between the BCR and NP released from MV-
infected cells. In this context, all APCs expressing FcgRII
could efficiently internalize NP before any production of
specific anti-NP antibodies. This receptor-mediated endo-
cytosis without opsonization could target NP to an endo-
cytic compartment where formation of MHC class II–peptide
occurs, and could explain the efficient CD41 T helper cell
response against NP observed during MV infection.
Cross-linking of the BCR with either human FcgRIIb1,
IIb2, or murine FcgRIIb1 molecules results in inhibition of
antibody production. This inhibition involves the immu-
noreceptor tyrosine-based inhibitory motif of FcgRIIb that
recruits phosphatases (42). It was originally thought that the
BCR and FcR have to be co-ligated for this mechanism of
inhibition. In the present study, we show that engagement
of the BCR is not required for the development of the
NP-mediated inhibition of Ig synthesis inasmuch as NP
downregulates the Ig response by CD40-activated B cells.
One plausible explanation is that the sole cross-linking of
FcR is sufficient to transduce a negative regulatory signal.
This hypothesis is compatible with the fact that the recom-
binant NP has an oligomeric structure thus susceptible to
efficiently cross-link the FcgRII on B cells. It is notewor-
thy that no inhibition of B cell proliferation was observed
in the presence of NP (data not shown). These results ex-
tend previous studies showing that antigen–antibody com-
plexes bound to murine B lymphocytes via FcgR inhibit
their antibody response, but not their proliferation in re-
sponse to F(ab9)2 anti-m and lymphokines (43, 44). Our data
thus support the notion that NP would rather interfere
with the plasma cell differentiation pathway. Determina-
tion of the exact nature of inhibitory signal(s) generated by
interaction between NP and FcgRII will need further in-
vestigations. It was previously demonstrated that in vitro,
MV infection inhibits Ig secretion from PWM-stimulated
PBL cultures (45) and impairs the proliferative response of
B cells to mitogens (46). This inhibition affects the early
phase of B lymphocyte differentiation and could be due to
a blockade of the late G1 phase of the cell cycle (47). It is
thus probable that, besides NP, additional mechanisms op-
erate during the MV-induced immunosuppression. In line
with such a hypothesis, recent data suggest that the MV H
and F proteins could mediate inhibition of lymphocyte
proliferation in uninfected cells (48). In vivo, the downreg-
ulation of antibody production during measles infection
could involve two different mechanisms, one acting on B
Table 2. NP Inhibits the Ig Response of Activated B Cells
Stimulation NP
Ig synthesis
IgG IgM IgA
mg/ml
22 1.0 1.4 ,0.2
aIg 2 2.9 0.2 0.3
aIg 1 IL-2 1 IL-10 2 7.7 18.7 0.4
aIg 1 IL-2 1 IL-10 1 2.9 (62) 7.1 (62) ,0.2 (.50)
CD40L 2 2.9 7.3 0.3
CD40L 1 IL-2 1 IL-10 2 89.5 73.7 12.7
CD40L 1 IL-2 1 IL-10 1 43.4 (52) 36.6 (50) 6.5 (49)
B cells were stimulated with either an anti-Ig antibody or a CD40L
transfectant in combination with IL-2 and IL-10, with or without an
optimal dose (30 ng/ml) of NP. Ig synthesis was evaluated in 12-d cul-
ture supernatants. Values in brackets indicate the percentage of inhibi-
tion calculated as indicated in Materials and Methods. Standard devia-
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cell proliferation, and the other one mediated by NP acting
on B cell differentiation in plasma cell.
During measles infection, defects in the responses of both
lymphocytes and monocytes have been reported (49). Mea-
sles virus infection of primary human monocytes leads to a
marked suppression of IL-12, some downregulation of IL-10,
and an unaltered TNF-a and IL-6 production. The inter-
action between MV and its cellular receptor, the human
CD46, could inhibit IL-12 production (50). However, the
possibility that cross-linking of FcgR by NP is involved in
modulating monokine production needs to be investigated.
It is very puzzling to note that viruses use molecules of
the immune system for their entry, but also for the subver-
sion of regulatory pathways. This subversion could not
only implicate viral proteins of the envelope like H or F,
but also internal viral protein such as MV NP that decreases
in vitro Ig secretion. Other viral NP could perturb immune
response as rabies and influenza NP. Rabies NP could act
as a superantigen leading to T cell activation (21) and either
clonal deletion or anergy. NP from influenza A virus inhib-
its polymorphonuclear neutrophils functions such as chemo-
taxis and superoxide production suggesting that NP could
play a role in secondary bacterial infections observed in pa-
tients infected with influenza virus (51).
In conclusion, our present findings suggest that during
acute phase of measles virus infection, NP specifically tar-
gets to the FcgRII-expressing cells and may play a role in
the MV-induced immunosuppression.
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